SynthesisProstate cancer and prostatic diseases2023
Head-to-head comparison of
Synthesis in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Pooled it
- Superiority of long axial field-of-viewEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Review
- Mapping the evolution of PET/MR research: a bibliometric analysis of publication trends, leading contributors, and conceptual frameworks (2011-2023).EJNMMI reports · 2024Article
- Advanced Imaging for Localized Prostate Cancer.Cancers · 2024Review
- The value ofDiscover oncology · 2024Article
- The superior detection rate of total-body [European journal of nuclear medicine and molecular imaging · 2024Article
- The Diagnostic Performance ofIranian journal of public health · 2024Review
- The EANM Focus 5 consensus on 'molecular imaging and theranostics in prostate cancer': the future begins today.European journal of nuclear medicine and molecular imaging · 2024Article
- Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.Experimental hematology & oncology · 2024Review
- Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.Journal of cancer research and clinical oncology · 2023Article
- Hybrid imaging with [Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOur meta-analysis aimed to evaluate the diagnostic performance of
methodsWe searched for relevant articles in PubMed and Embase until February 2022. Studies evaluating head-to-head comparison of
resultsA total of 5 studies with 219 patients were included in the analysis. The pooled overall detection rates of
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.